Nicotinamide riboside - ChromaDex

Drug Profile

Nicotinamide riboside - ChromaDex

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Cornell University; Dartmouth College; Washington University
  • Developer ChromaDex; National Institutes of Health (USA)
  • Class Amides; Nicotinic-acids; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cockayne syndrome

Most Recent Events

  • 11 Nov 2016 ChromaDex plans a phase I/II trial for Cockayne Syndrome in USA
  • 14 Jun 2016 ChromaDex has patent protection for nicotinamide riboside in several countries (ChromaDex website, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top